US Plans 100% Tariff on Certain Drugs Unless Production Moves to U.S.

In a recent declaration, President Trump revealed that starting October 1st, a substantial 100% tariff would be levied on all branded and patented pharmaceutical goods imported into the United States.

This hefty tariff, however, will not affect companies that have already begun implementing facilities to manufacture drugs within the U.S., according to Trump.

Conditions for Exemption

Trump clarified that any project that is actively constructing a pharmaceutical plant—whether groundwork has commenced or construction is underway—will be exempt from this new tariff.

“For pharmaceutical items produced on-site where construction activity has started, the tariff will not apply,” he noted in a statement.

Additional Tariffs Announced

Alongside the drug tariffs, Trump also declared new import duties: A 25% tariff on large trucks and a 50% tariff on 'all Kitchen Cabinets, Bathroom Vanities, and related products,' all set to take effect at the beginning of October.

In a previous statement, Trump hinted that pharmaceutical tariffs might skyrocket to as high as 250% later on.

Escalating Tariff Rates

Initially, a minor tariff will be placed on pharmaceuticals, with plans to elevate this to 150% within 12 to 18 months, eventually reaching a peak of 250%.

Ongoing Investigations

The administration is also probing imports of various industrial goods, which includes robotics and medical apparatus, potentially leading to additional tariffs.

The Department of Commerce has extended investigations to incorporate protective gear like surgical masks and respirators, along with medical tools, but pharmaceutical imports are subject to a separate probe, distinct from these investigations.

New tariffs stemming from these inquiries will augment Trump's country-specific tariffs, though some accords, such as those with the EU and Japan, may offer these regions some protection against these increased fees.